Experimental weight/metabolic drugs
Sobetirome vs Tesofensine
Tesofensine has Phase II weight-loss efficacy data; sobetirome has only early Phase I target-engagement/lipid evidence and no established obesity efficacy.
At a glance
Sobetirome
Tesofensine
Human evidence
Peer-reviewed reviews describe historical Phase I oral exposure with short-term lipid target engagement, including substantial LDL-C reductions, but a fully retrievable primary clinical report remains limited and development did not yield an approved therapy.
A randomized Phase II obesity trial showed dose-dependent weight loss, and smaller physiology studies suggest appetite/satiety effects are more prominent than a large 24-hour energy-expenditure increase. Tesomet combination data exist in hypothalamic obesity.
Research focus
Dyslipidaemia, metabolic and neurodegenerative research
Obesity/weight-management research
Regulatory status
No FDA/EMA-approved sobetirome medicine identified.
Not FDA-approved; FDA has cited tesofensine as ineligible for use in US 503A compounding in enforcement material.
Route / formulation
This is not a peptide and should not be grouped with peptide pharmacology.
This is not a peptide. Research results do not validate unregulated oral capsules.
No head-to-head evidence Tesofensine has Phase II weight-loss efficacy data; sobetirome has only early Phase I target-engagement/lipid evidence and no established obesity efficacy.